Pacira Biosciences Inc Financials
Pacira Biosciences Inc (PCRX) reported $746.2M in revenue over the twelve months to Jun 30, 2026, up 5.7% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Pacira’s business runs on very high product margins, but operating expense intensity keeps reported earnings far below its cash output.
In the latest year, gross margin reached79.4% but operating margin was only2.6% ; nearly all of the benefit was absorbed by SG&A and R&D intensity rather than weak production economics. That is why cash earnings looked much stronger than accounting profit, with operating cash flow at$152.0M versus net income of$7.0M .
The balance sheet still reads liquid but actively managed: the current ratio was 4.5x and long-term debt was
Working capital became a bigger cash claim in the latest year: inventory rose to
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Pacira Biosciences Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Pacira Biosciences Inc has an operating margin of 2.6%, meaning the company retains $3 of operating profit per $100 of revenue. This results in a moderate score of 36/100, indicating healthy but not exceptional operating efficiency. This is up from -10.5% the prior year.
Pacira Biosciences Inc's revenue grew a modest 3.6% year-over-year to $726.4M. This slow but positive growth earns a score of 45/100.
Pacira Biosciences Inc has a moderate D/E ratio of 0.54. This balance of debt and equity financing earns a leverage score of 31/100.
With a current ratio of 4.54, Pacira Biosciences Inc holds $4.54 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 88/100.
Pacira Biosciences Inc converts 18.8% of revenue into free cash flow ($136.7M). This strong cash generation earns a score of 88/100.
Pacira Biosciences Inc's ROE of 1.0% shows moderate profitability relative to equity, earning a score of 32/100. This is up from -12.8% the prior year.
Pacira Biosciences Inc scores 1.89, placing it in the grey zone between 1.81 and 2.99. The score is driven primarily by a large market capitalization ($1.0B) relative to total liabilities ($571.8M). This signals moderate financial risk that warrants monitoring.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Pacira Biosciences Inc passes 8 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
Pacira Biosciences Inc reported $7.0M of net income while generating $152.0M in operating cash flow. The ratio between the two is outside the range this page publishes as a per-dollar figure, so both figures are given instead.
Pacira Biosciences Inc earns $1.10 in operating income for every $1 of interest expense ($19.2M vs $17.4M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Pacira Biosciences Inc generated $726.4M in revenue in fiscal year 2025. This represents an increase of 3.6% from the prior year.
Pacira Biosciences Inc's EBITDA was $110.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 1935.7% from the prior year.
Pacira Biosciences Inc reported $7.0M in net income in fiscal year 2025. This represents an increase of 107.0% from the prior year.
Pacira Biosciences Inc earned $0.16 per diluted share (EPS) in fiscal year 2025. This represents an increase of 107.4% from the prior year.
Cash & Balance Sheet
Pacira Biosciences Inc generated $136.7M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 23.5% from the prior year.
Pacira Biosciences Inc held $158.5M in cash against $372.2M in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Pacira Biosciences Inc's gross margin was 79.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 3.7 percentage points from the prior year.
Pacira Biosciences Inc's operating margin was 2.6% in fiscal year 2025, reflecting core business profitability. This is up 13.1 percentage points from the prior year.
Pacira Biosciences Inc's net profit margin was 1.0% in fiscal year 2025, showing the share of revenue converted to profit. This is up 15.2 percentage points from the prior year.
Pacira Biosciences Inc's ROE was 1.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 13.8 percentage points from the prior year.
Capital Allocation
Pacira Biosciences Inc invested $117.3M in research and development in fiscal year 2025. This represents an increase of 43.8% from the prior year.
Pacira Biosciences Inc spent $148.3M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents an increase of 493.3% from the prior year.
Pacira Biosciences Inc invested $15.3M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 44.2% from the prior year.
PCRX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $192.4M+8.5% | $177.4M-9.9% | $196.9M+9.7% | $179.5M-0.9% | $181.1M+7.2% | $168.9M-9.8% | $187.3M+11.1% | $168.6M |
| Cost of Revenue | $44.2M+21.3% | $36.4M-9.6% | $40.3M+17.6% | $34.3M-16.1% | $40.9M+19.1% | $34.3M-14.0% | $39.9M+2.6% | $38.9M |
| Gross Profit | $148.2M+5.2% | $141.0M-10.0% | $156.6M+7.8% | $145.2M+3.6% | $140.2M+4.2% | $134.6M-8.7% | $147.4M+13.6% | $129.7M |
| R&D Expenses | $30.2M+7.7% | $28.1M-25.7% | $37.8M+45.6% | $26.0M-7.9% | $28.2M+11.3% | $25.3M+6.0% | $23.9M+25.1% | $19.1M |
| SG&A Expenses | $91.8M-2.3% | $93.9M-7.5% | $101.6M+10.7% | $91.8M+3.6% | $88.6M+2.1% | $86.8M+9.0% | $79.6M+7.1% | $74.3M |
| Operating Income | $4.3M-38.2% | $6.9M+195.0% | $2.3M-63.2% | $6.4M-25.1% | $8.5M+327.1% | $2.0M-91.9% | $24.7M+117.7% | -$139.5M |
| Interest Expense | $3.6M-2.1% | $3.7M-5.0% | $3.9M-9.0% | $4.3M-8.9% | $4.7M+2.5% | $4.6M-2.1% | $4.7M-0.2% | $4.7M |
| Income Tax | -$2.1M-200.8% | $2.1M+295.3% | -$1.1M-126.1% | $4.1M+40.1% | $2.9M-25.0% | $3.9M-58.9% | $9.5M+105.7% | $4.6M |
| Net Income | $4.7M+59.6% | $2.9M+81.9% | $1.6M-70.5% | $5.4M+212.1% | -$4.8M-200.7% | $4.8M-69.9% | $16.0M+111.2% | -$143.5M |
| EPS (Diluted) | $0.12+71.4% | $0.07+75.0% | $0.04-66.7% | $0.12+209.1% | -$0.11-210.0% | $0.10-71.4% | $0.35+111.3% | -$3.11 |
PCRX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.2B+2.9% | $1.2B-4.5% | $1.3B-2.5% | $1.3B-15.6% | $1.5B-3.1% | $1.6B+2.1% | $1.6B+2.1% | $1.5B |
| Current Assets | $615.2M+19.5% | $515.0M-6.0% | $548.0M-2.6% | $562.8M-24.5% | $745.6M-1.9% | $760.0M+2.0% | $745.1M+8.0% | $690.0M |
| Cash & Equivalents | $205.9M+42.7% | $144.3M-9.0% | $158.5M+7.4% | $147.6M-50.9% | $300.5M+5.9% | $283.6M+2.5% | $276.8M+12.5% | $246.0M |
| Inventory | $134.6M-10.5% | $150.4M-1.6% | $152.9M-3.1% | $157.7M+6.4% | $148.2M+10.8% | $133.8M+6.8% | $125.3M+12.0% | $111.9M |
| Accounts Receivable | $132.4M+5.4% | $125.6M+1.3% | $124.1M+7.6% | $115.3M+0.8% | $114.4M+9.2% | $104.7M-7.6% | $113.3M+12.6% | $100.7M |
| Goodwill | $19.6M-0.7% | $19.8M-2.2% | $20.2M-0.5% | $20.3M+0.1% | $20.3M-5.7% | $21.5M | $0 | $0 |
| Total Liabilities | $572.0M+3.1% | $554.6M-3.0% | $571.8M+0.3% | $570.4M-26.8% | $779.5M-1.1% | $788.1M+1.7% | $775.2M+0.4% | $772.1M |
| Current Liabilities | $122.0M+12.2% | $108.8M-9.8% | $120.6M+12.6% | $107.1M-65.8% | $313.2M-0.5% | $314.7M+1.6% | $309.9M+1.1% | $306.4M |
| Long-Term Debt | $363.1M-1.2% | $367.7M-1.2% | $372.2M-1.2% | $376.7M-35.1% | $580.5M-0.5% | $583.4M+52.1% | $383.5M | N/A |
| Total Equity | $672.0M+2.8% | $653.9M-5.7% | $693.1M-4.7% | $727.2M-4.0% | $757.8M-5.1% | $798.5M+2.6% | $778.3M+3.8% | $749.6M |
| Retained Earnings | -$191.8M+2.4% | -$196.4M+1.5% | -$199.3M+0.8% | -$201.0M+2.6% | -$206.4M-2.4% | -$201.5M+2.3% | -$206.4M+7.2% | -$222.4M |
PCRX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $57.5M+123.8% | $25.7M-41.2% | $43.7M-28.2% | $60.8M+406.4% | $12.0M-66.1% | $35.5M+7.0% | $33.1M-38.6% | $53.9M |
| Capital Expenditures | $1.3M-51.0% | $2.7M+1149.5% | $218K-94.4% | $3.9M+43.5% | $2.7M-68.4% | $8.5M+303.6% | $2.1M-48.2% | $4.1M |
| Free Cash Flow | $56.1M+144.5% | $23.0M-47.2% | $43.5M-23.7% | $57.0M+511.5% | $9.3M-65.4% | $26.9M-13.2% | $31.0M-37.8% | $49.8M |
| Investing Cash Flow | $11.8M-39.5% | $19.4M+0.6% | $19.3M-55.7% | $43.6M-29.8% | $62.2M+342.5% | -$25.6M-6864.4% | -$368K+99.3% | -$52.2M |
| Financing Cash Flow | -$7.7M+87.1% | -$59.4M-15.0% | -$51.7M+79.9% | -$257.5M-347.7% | -$57.5M-1820.7% | -$3.0M-53.1% | -$2.0M+31.3% | -$2.8M |
| Share Buybacks | $0-100.0% | $50.0M+3.7% | $48.2M-3.6% | $50.0M0.0% | $50.0M | $0 | $0 | $0 |
Not reported in any period shown, so not listed: Dividends Paid.
PCRX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 77.0%-2.4pp | 79.5%-0.1pp | 79.5%-1.4pp | 80.9%+3.5pp | 77.4%-2.3pp | 79.7%+1.0pp | 78.7%+1.8pp | 77.0% |
| Operating Margin | 2.2%-1.7pp | 3.9%+2.7pp | 1.2%-2.4pp | 3.5%-1.1pp | 4.7%+3.5pp | 1.2%-12.0pp | 13.2%+96.0pp | -82.8% |
| Net Margin | 2.4%+0.8pp | 1.6%+0.8pp | 0.8%-2.2pp | 3.0%+5.7pp | -2.7%-5.5pp | 2.9%-5.7pp | 8.6%+93.7pp | -85.1% |
| Return on Equity | 0.7%+0.2pp | 0.4%+0.2pp | 0.2%-0.5pp | 0.8%+1.4pp | -0.6%-1.2pp | 0.6%-1.5pp | 2.1%+21.2pp | -19.1% |
| Return on Assets | 0.4%+0.1pp | 0.2%+0.1pp | 0.1%-0.3pp | 0.4%+0.7pp | -0.3%-0.6pp | 0.3%-0.7pp | 1.0%+10.5pp | -9.4% |
| Current Ratio | 5.04+0.3x | 4.73+0.2x | 4.54-0.7x | 5.26+2.9x | 2.380.0x | 2.410.0x | 2.40+0.2x | 2.25 |
| Debt-to-Equity | 0.540.0x | 0.560.0x | 0.540.0x | 0.52-0.2x | 0.770.0x | 0.73+0.2x | 0.49-0.5x | 1.03 |
| FCF Margin | 29.2%+16.2pp | 12.9%-9.1pp | 22.1%-9.7pp | 31.7%+26.6pp | 5.1%-10.8pp | 15.9%-0.6pp | 16.6%-13.0pp | 29.6% |
Similar Companies
Where Pacira Biosciences Inc Ranks
Frequently Asked Questions
What is Pacira Biosciences Inc's annual revenue?
Pacira Biosciences Inc (PCRX) reported $726.4M in total revenue for fiscal year 2025. This represents a 3.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Pacira Biosciences Inc's revenue growing?
Pacira Biosciences Inc (PCRX) revenue grew by 3.6% year-over-year, from $701.0M to $726.4M in fiscal year 2025.
Is Pacira Biosciences Inc profitable?
Yes, Pacira Biosciences Inc (PCRX) reported a net income of $7.0M in fiscal year 2025, with a net profit margin of 1.0%.
What is Pacira Biosciences Inc's EBITDA?
Pacira Biosciences Inc (PCRX) had EBITDA of $110.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Pacira Biosciences Inc have?
As of fiscal year 2025, Pacira Biosciences Inc (PCRX) had $158.5M in cash and equivalents against $372.2M in long-term debt.
What is Pacira Biosciences Inc's gross margin?
Pacira Biosciences Inc (PCRX) had a gross margin of 79.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Pacira Biosciences Inc's operating margin?
Pacira Biosciences Inc (PCRX) had an operating margin of 2.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Pacira Biosciences Inc's net profit margin?
Pacira Biosciences Inc (PCRX) had a net profit margin of 1.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Pacira Biosciences Inc's return on equity (ROE)?
Pacira Biosciences Inc (PCRX) has a return on equity of 1.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Pacira Biosciences Inc's free cash flow?
Pacira Biosciences Inc (PCRX) generated $136.7M in free cash flow during fiscal year 2025. This represents a -23.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Pacira Biosciences Inc's operating cash flow?
Pacira Biosciences Inc (PCRX) generated $152.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Pacira Biosciences Inc's total assets?
Pacira Biosciences Inc (PCRX) had $1.3B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Pacira Biosciences Inc's capital expenditures?
Pacira Biosciences Inc (PCRX) invested $15.3M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Pacira Biosciences Inc spend on research and development?
Pacira Biosciences Inc (PCRX) invested $117.3M in research and development during fiscal year 2025.
What is Pacira Biosciences Inc's current ratio?
Pacira Biosciences Inc (PCRX) had a current ratio of 4.54 as of fiscal year 2025, which is generally considered healthy.
What is Pacira Biosciences Inc's debt-to-equity ratio?
Pacira Biosciences Inc (PCRX) had a debt-to-equity ratio of 0.54 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Pacira Biosciences Inc's return on assets (ROA)?
Pacira Biosciences Inc (PCRX) had a return on assets of 0.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Pacira Biosciences Inc's Altman Z-Score?
Pacira Biosciences Inc (PCRX) has an Altman Z-Score of 1.89, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Pacira Biosciences Inc's Piotroski F-Score?
Pacira Biosciences Inc (PCRX) has a Piotroski F-Score of 8 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Pacira Biosciences Inc's earnings high quality?
Pacira Biosciences Inc (PCRX) reported $7.0M of net income while generating $152.0M in operating cash flow. The ratio between the two is outside the range this page publishes as a per-dollar figure, so both figures are given instead. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Pacira Biosciences Inc cover its interest payments?
Pacira Biosciences Inc (PCRX) has an interest coverage ratio of 1.10x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Pacira Biosciences Inc?
Pacira Biosciences Inc (PCRX) scores 53 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.